Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Switzerland-based antibody therapy developer NovaGo Therapeutics, a spinout of University of Zurich, completed a CHF10m ($10m) series A round on Monday featuring biopharmaceutical company Neurimmune, which invested through a strategic partnership agreement. The round was led by venture capital fund Pureos Bioventures and the funding will be used to advance NovaGo’s regenerative medicines toward clinical…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.